HealthDay on MSN4d
GLP-1 RA Use Linked to Reduced Cirrhosis Risk in MASLD, DiabetesFor patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and diabetes, glucagon-like peptide 1 ...
A Cleveland Clinic study identified key factors that can impact the long-term weight loss of patients with obesity who were ...
The new Lemme GLP-1 Daily Capsules are being called an "Ozempic alternative." But do they really work — and if so, at what ...
The study concentrates on the FDA-approved injectable medications semaglutide and liraglutide. A study conducted by the ...
Some people lose more weight on drugs like Ozempic, Wegovy and Saxenda than others, and a new study reveals why that might be.
Amycretin, a dual pathway, oral weight loss drug, was found to be safe and tolerable in a phase 1 study and led to weight loss of up to 13% in people with overweight and obesity.
News Medical on MSN4d
Semaglutide vs. liraglutide: One-year weight loss efficacy in obesity and type 2 diabetesAmong patients receiving persistent medication at one year, 61% of patients prescribed semaglutide for obesity achieved at ...
UNSW medical researchers say more Australians with type 2 diabetes need to be offered add-on medications that would better ...
A new study identified key factors that can impact the long-term weight loss of patients with obesity who were prescribed injectable semaglutide or liraglutide for the treatment of type 2 diabetes or ...
Whether positive or negative, your mood may feel different on GLP-1 medications. Researchers share why that might be and how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback